Revolution Medicines reports positive Phase 3 pancreatic cancer data, raises $2.4B in capital

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read

Key Changes

• high

  Daraxonrasib nearly doubled median overall survival in second-line pancreatic cancer (13.2 vs 6.7 months, HR 0.40, p<0.0001) in Phase 3 RASolute 302 trial; company plans NDA submission to FDA using Commissioner's National Priority Voucher pathway.

  MD&A: RASolute 302 Phase 3 topline results verify on EDGAR →
• high

  Company raised $2.4B in capital through April 2026 equity and convertible debt offerings ($2.1B net) plus $250M Royalty Pharma Tranche 2 payment triggered by Phase 3 results, strengthening balance sheet to fund expanded clinical programs and commercial preparation.

  MD&A: April 2026 equity and convertible debt offerings; Royalty Pharma Tranche 2 funding verify on EDGAR →
• high

  Company initiated two new Phase 3 trials: RASolve 308 (zoldonrasib in first-line lung cancer) and plans RASolute 309 (daraxonrasib + zoldonrasib combination in first-line pancreatic cancer) for H2 2026, expanding registrational program across tumor types.

  MD&A: Expanded Phase 3 pancreatic cancer program; RASolve 308 Phase 3 trial in NSCLC verify on EDGAR →